Viral infections and the efficacy of PD-(L)1 inhibitors in virus-related cancers: Head and neck squamous cell carcinoma and hepatocellular carcinoma

CONCLUSION: Patients with advanced HNSCC and HCC, regardless of viral infection status, could benefit from ICI treatment. Patients with hepatitis B virus-associated HCC were more likely to benefit from ICI treatment than patients without viral infections.REGISTRATION: Our systematic review protocol was registered with the International Prospective Register of Systematic Reviews on March 27, 2020 (registration number CRD42020155326).PMID:34537483 | DOI:10.1016/j.intimp.2021.108128

Source: International Immunopharmacology - September 19, 2021 Category: Allergy & Immunology Authors: Ting Liu Qing Li Zhen Lin Peipei Wang Yueyun Chen Yang Fu Zhenyu Ding Source Type: research